NZ764310A - Antibacterial compounds - Google Patents

Antibacterial compounds

Info

Publication number
NZ764310A
NZ764310A NZ764310A NZ76431018A NZ764310A NZ 764310 A NZ764310 A NZ 764310A NZ 764310 A NZ764310 A NZ 764310A NZ 76431018 A NZ76431018 A NZ 76431018A NZ 764310 A NZ764310 A NZ 764310A
Authority
NZ
New Zealand
Prior art keywords
compounds
antibacterial compounds
diseases
enterobacteriaceaebacterial
enterobacteriaceae
Prior art date
Application number
NZ764310A
Other languages
English (en)
Inventor
Paul Meo
Mohammed Nawaz Khan
Cedric Charrier
Original Assignee
Discuva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ764310(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Discuva Ltd filed Critical Discuva Ltd
Publication of NZ764310A publication Critical patent/NZ764310A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Warehouses Or Storage Devices (AREA)
NZ764310A 2017-11-03 2018-11-02 Antibacterial compounds NZ764310A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1718285.8A GB201718285D0 (en) 2017-11-03 2017-11-03 Antibacterial Compounds
PCT/GB2018/053183 WO2019086890A1 (en) 2017-11-03 2018-11-02 Antibacterial compounds

Publications (1)

Publication Number Publication Date
NZ764310A true NZ764310A (en) 2023-04-28

Family

ID=60664899

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ764310A NZ764310A (en) 2017-11-03 2018-11-02 Antibacterial compounds

Country Status (23)

Country Link
US (2) US11345694B2 (enExample)
EP (2) EP3704105B9 (enExample)
JP (2) JP7348897B2 (enExample)
KR (1) KR102470319B1 (enExample)
CN (1) CN111566099B (enExample)
AU (1) AU2018361828B2 (enExample)
BR (1) BR112020008531A2 (enExample)
CA (1) CA3081423A1 (enExample)
CL (2) CL2020001147A1 (enExample)
CO (1) CO2020005420A2 (enExample)
EA (1) EA202091118A1 (enExample)
ES (1) ES3005164T3 (enExample)
GB (1) GB201718285D0 (enExample)
GE (1) GEP20237522B (enExample)
IL (1) IL274229B2 (enExample)
MA (1) MA50504A (enExample)
MX (2) MX2020004562A (enExample)
NZ (1) NZ764310A (enExample)
PE (2) PE20211390A1 (enExample)
SG (1) SG11202003717UA (enExample)
UA (1) UA128475C2 (enExample)
WO (1) WO2019086890A1 (enExample)
ZA (1) ZA202002093B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
HUE066783T2 (hu) 2018-04-18 2024-09-28 Constellation Pharmaceuticals Inc Metil módosító enzimek modulátorai, ezek készítményei és alkalmazásuk
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN111635372B (zh) * 2020-06-28 2022-05-27 齐鲁工业大学 一种恶唑酮衍生物及其合成方法
EP4333854A1 (en) * 2021-05-03 2024-03-13 Discuva Ltd. Antibacterial compound
EP4484609A1 (en) 2022-02-21 2025-01-01 Mitsui Chemicals, Inc. Metal member, metal-resin composite body, and method for producing metal member
CN120208965B (zh) * 2025-05-28 2025-08-12 四川大学 靶向革兰氏阴性菌外膜组装关键蛋白质机器的4-(吡啶-4-基)-1h-咪唑-2-胺类衍生物、组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869348B (en) 1985-12-12 1987-10-28 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
AR029803A1 (es) * 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
WO2005047266A1 (en) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
WO2005085241A1 (ja) * 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2513064B1 (en) * 2009-12-17 2018-07-04 Katholieke Universiteit Leuven K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
GB201016261D0 (en) 2010-09-28 2010-11-10 Univ Leuven Kath Compounds for controlling biofilms and process for their production
WO2012135016A2 (en) 2011-03-25 2012-10-04 North Carolina State University Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
PL2731949T3 (pl) * 2011-07-13 2018-10-31 Tiumbio Co., Ltd. 2-pirydylo podstawione imidazole jako inhibitory alk5 i/lub alk4
US8840912B2 (en) 2012-01-09 2014-09-23 North Carolina State University Imidazole derivatives useful for controlling microbial growth
KR102405136B1 (ko) * 2014-05-16 2022-06-07 아트리바 테라퓨틱스 게엠베하 인플루엔자 바이러스 및 에스. 아우레우스 공감염에 대한 신규한 항-감염 전략
KR20170122799A (ko) 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-β 억제제
US20180044316A1 (en) 2015-03-05 2018-02-15 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds

Also Published As

Publication number Publication date
AU2018361828A1 (en) 2020-05-28
CA3081423A1 (en) 2019-05-09
MA50504A (fr) 2020-09-09
EP3704105A1 (en) 2020-09-09
CO2020005420A2 (es) 2020-07-31
US20220372027A1 (en) 2022-11-24
CL2020001147A1 (es) 2020-08-14
ES3005164T9 (en) 2025-03-24
CL2021002263A1 (es) 2022-04-01
PE20221006A1 (es) 2022-06-15
US11345694B2 (en) 2022-05-31
SG11202003717UA (en) 2020-05-28
PE20211390A1 (es) 2021-07-27
IL274229B1 (en) 2023-01-01
EP4606375A3 (en) 2025-11-19
GEP20237522B (en) 2023-08-10
CN111566099A (zh) 2020-08-21
MX2021010246A (es) 2021-09-21
AU2018361828B2 (en) 2023-05-18
CN111566099B (zh) 2023-06-02
JP2021501756A (ja) 2021-01-21
IL274229B2 (en) 2023-05-01
MX2020004562A (es) 2020-08-13
EP4606375A2 (en) 2025-08-27
US20210163460A1 (en) 2021-06-03
EP3704105B1 (en) 2024-10-16
UA128475C2 (uk) 2024-07-24
EP3704105B9 (en) 2025-03-05
IL274229A (en) 2020-06-30
KR102470319B1 (ko) 2022-11-25
ES3005164T3 (en) 2025-03-14
EA202091118A1 (ru) 2020-08-06
KR20200084875A (ko) 2020-07-13
GB201718285D0 (en) 2017-12-20
ZA202002093B (en) 2023-11-29
JP7348897B2 (ja) 2023-09-21
BR112020008531A2 (pt) 2020-10-20
JP2022025116A (ja) 2022-02-09
WO2019086890A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
ZA202002093B (en) Antibacterial compounds
PH12019500360A1 (en) Antibiotic compounds
EA201691766A1 (ru) Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
MX2016009898A (es) Tratamientos para acne resistente.
EA201990043A1 (ru) Антибактериальные соединения
WO2015003816A3 (en) Cystobactamides
NZ713621A (en) Compounds and methods of treating infections
EA201792006A1 (ru) Антимикробные соединения и способы их получения и их применение
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
NZ724798A (en) Polymyxin derivatives as antimicrobial compounds
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
EP3294761A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
MX2016009248A (es) Compuestos que contienen nitrogeno y su uso como agentes antibacterianos.
MX2016001855A (es) Nuevos aza-oxo-indoles para el tratamiento y profilaxis de la infeccion por virus sincitial respiratorio.
MX389771B (es) Compuestos de minociclina para biodefensas.
MX2015012472A (es) Derivados de manosa para el tratamiento de infecciones bacterianas.
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
IN2013MU03216A (enExample)
MX2017012539A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2024 BY DENNEMEYER + CO. SARL

Effective date: 20231023

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2025 BY DENNEMEYER ET CO

Effective date: 20241022

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 NOV 2026 BY MS. MANDY LAUBACH

Effective date: 20251021